Abstract:Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, affecting nearly 2 million people worldwide. The etiology of MS is multifactorial: Approximately 30% of the MS risk is genetic, which implies that the remaining ~70% is environmental, with a number of factors proposed. One recently implicated risk factor for MS is the composition of the gut microbiome. Numerous case-control studies have identified changes in gut microbiota composition of people with MS (pwMS) compared with healthy control individuals, and more recent studies in animal models have begun to identify the causative microbes and underlying mechanisms. Here, we review some of these mechanisms, with a specific focus on the role of host genetic variation, dietary inputs, and gut microbial metabolism, with a particular emphasis on short-chain fatty acid and tryptophan metabolism. We put forward a model where, in an individual genetically susceptible to MS, the gut microbiota and diet can synergize as potent environmental modifiers of disease risk and possibly progression, with diet-dependent gut microbial metabolites serving as a key mechanism. We also propose that specific microbial taxa may have divergent effects in individuals carrying distinct variants of MS risk alleles or other polymorphisms, as a consequence of host gene-by-gut microbiota interactions. Finally, we also propose that the effects of specific microbial taxa, especially those that exert their effects through metabolites, are highly dependent on the host dietary intake. What emerges is a complex multifaceted interaction that has been challenging to disentangle in human studies, contributing to the divergence of findings across heterogeneous cohorts with differing geography, dietary preferences, and genetics. Nonetheless, this provides a complex and individualized, yet tractable, model of how the gut microbiota regulate susceptibility to MS, and potentially progression of this disease. Thus, we conclude that prophylactic or therapeutic modulation of the gut microbiome to prevent or treat MS will require a careful and personalized consideration of host genetics, baseline gut microbiota composition, and dietary inputs.

The Role of Gut-derived Short-Chain Fatty Acids in Multiple Sclerosis

Dietary fatty acids and susceptibility to multiple sclerosis

Role of Gut Microbiota in Multiple Sclerosis and Potential Therapeutic Implications

The Role of Gut Dysbiosis and Potential Approaches to Target the Gut Microbiota in Multiple Sclerosis

The Immunomodulatory Potential of Short-Chain Fatty Acids in Multiple Sclerosis

Gut microbiota in multiple sclerosis and animal models

Gastrointestinal Tract, Microbiota and Multiple Sclerosis (MS) and the Link Between Gut Microbiota and CNS

Gut Flora in Multiple Sclerosis: Implications for Pathogenesis and Treatment

Interaction of the Gut Microbiome and Immunity in Multiple Sclerosis: Impact of Diet and Immune Therapy

Feeding the gut microbiome: impact on multiple sclerosis

The Gut Microbiota and Associated Metabolites in Multiple Sclerosis

Gut–Brain Interactions and Their Impact on Astrocytes in the Context of Multiple Sclerosis and Beyond

The Role of Intestinal Microbiota and Probiotics Supplementation in Multiple Sclerosis Management

Modulating the Gut Microbiome in Multiple Sclerosis Management: A Systematic Review of Current Interventions

The role of diet in multiple sclerosis: A review

Gut Dysbiosis and Lack of Short Chain Fatty Acids in a Chinese Cohort of Patients with Multiple Sclerosis

The role of the gut microbiota and microbial metabolites in neuroinflammation

Gut Microbiota in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Current Applications and Future Perspectives

Modulation of multiple sclerosis risk and pathogenesis by the gut microbiota: Complex interactions between host genetics, bacterial metabolism, and diet

The role of gut microbiome and associated metabolome in the regulation of neuroinflammation in multiple sclerosis and its implications in attenuating chronic inflammation in other inflammatory and autoimmune disorders

Gut microbiota, cannabinoid system and neuroimmune interactions: New perspectives in multiple sclerosis